Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, parallel group, phase 4, multi-center study of Vesicare (solifenacin succinate) in overactive bladder (OAB) subjects to evaluate symptom bother and health related quality of life VIBRANT: VESIcare Investigation of Bother And Quality of Life in Subjects with OAB

Next Previous
Trial Profile

A randomized, double-blind, placebo-controlled, parallel group, phase 4, multi-center study of Vesicare (solifenacin succinate) in overactive bladder (OAB) subjects to evaluate symptom bother and health related quality of life VIBRANT: VESIcare Investigation of Bother And Quality of Life in Subjects with OAB

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Solifenacin (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms VIBRANT
  • Sponsors Astellas Pharma

    • Most Recent Events

    • 01 Jan 2010 Secondary endpoint 'Quality of life instrument' (change in HRQL total and domain scores on the OAB-q) has been met.
    • 16 May 2009 Results have been presented at the 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 06 May 2009 Primary endpoint 'Overactive Bladder Questionnaire' (change from baseline in OAB-q symptom bother scale score at 12 weeks) has been met.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top